A protein tyrosine phosphatase inhibitor accelerates angiogenesis in a rat model of hindlimb ischemia

Journal of Cardiovascular Pharmacology

Volumn 44, Issue 4, 2004, Pages 460-465

  Sugano, Masahiro ^a   Tsuchida, Keiko ^a   Makino, Naoki ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Hindlimb ischemia; Protein tyrosine phosphatase; Vanadates

Indexed keywords

PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; VANADATE SODIUM; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY DENSITY; CONTROLLED STUDY; ENZYME ACTIVATION; FEMORAL ARTERY; IMMUNOHISTOCHEMISTRY; LIMB ISCHEMIA; MALE; MUSCLE ISCHEMIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; HINDLIMB; ISCHEMIA; MALE; MUSCLE, SKELETAL; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEIN-TYROSINE-PHOSPHATASE; RATS; RATS, WISTAR; TIME FACTORS; VANADATES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 4644325681     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000143275.45289.0a     Document Type: Article

References (34)

1. Tsurumi Y, Kearney M, Chen D, et al. Treatment of acute limb ischemia by intramuscular injection of vascular endothelial growth factor gene. Circulation. 1997;96(suppl II):II382-II388.
2. Takeshita S, Zheng LP, Brogi E, et al. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest. 1994;93:662-670.
3. Isner JM, Pieczek A, Schainfeld R, et al. Clinical evidence ofangiogenesis after arterial gene transfer of phVEGF165 in patient with ischemic limb. Lancet. 1996;348:370-374.
4. Baumgartner I, Pieczek A, Manor O, et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation. 1998;97:1114-1123.
5. Berkman R, Merrill M, Reinhold W. Expression of the vascular permeability/vascular endothelial growth factor gene in central nervous system neoplasms. J Clin Invest. 1993;91:153-159.
6. Shweiki D, Itin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359:843-845.
7. Heldin CH. Dimerization of cell surface receptors in signal transduction. Cell. 1995;80:213-223.
8. Waltenberger J, Claesson-Welsh L, Siegbahn A, et al. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem. 1994;269:26988-26995.
9. Wo YY, McCormack AL, Shabanowitz J, et al. Sequencing, cloning, and expression of human red cell-type acid phosphatase, a cytoplasmic phosphotyrosyl protein phosphatase. J Biol Chem. 1992;267:10856-10865.
10. Sugano M, Tsuchida K, Makino N. Intramuscular gene transfer of soluble TNF-alpha receptor 1 activates vascular endothelial growth factor receptor (KDR/flk-1) and accelerates angiogenesis in a rat model of hindlimb ischemia. Circulation. 2004;109:797-802.
11. Guo DQ, Wu LW, Dunbar JD, et al. Tumor necrosis factor employs a protein-tyrosine phosphatase to inhibit activation of KDR and vascular endothelial cell growth factor-induced endothelial cell proliferation. J Biol Chem. 2000;275:11216-11221.
12. Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature. 1995;376:62-66.
13. Fong GH, Rossant J, Gertsenstein M, et al. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature. 1995;376:66-70.
14. Hiratsuka S, Minowa O, Kuno J, et al. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci USA. 1998;95:9349-9354.
15. Wu LW, Mayo LD, Dunbar JD, et al. Utilization of distinct signaling pathways by receptors for vascular endothelial cell growth factor and other mitogens in the induction of endothelial cell proliferation. J Biol Chem. 2000;275:5096-5103.
16. Guo D, Jia Q, Song HY, et al. Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation. J Biol Chem. 1995;270:6729-6733.
17. Thakker GD, Hajjar DP, Muller WA, et al. The role of phosphatidylinositol 3-kinase in vascular endothelial growth factor signaling. J Biol Chem. 1999;274:10002-10007.
18. Fujio Y, Walsh K. Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. J Biol Chem. 1999;274:16349-16354.
19. Gerber HP, McMurtrey A, Kowalski J, et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem. 1998;273:30336-30343.
20. Soeda S, Shimada T, Koyanagi S, et al. An attempt to promote neovascularization by employing a newly synthesized inhibitor of protein tyrosine phosphatase. FEBS Lett. 2002;524:54-58.
21. Gao N, Ding M, Zheng JZ, et al. Vanadate-induced expression of hypoxia-inducible factor 1 alpha and vascular endothelial growth factor through phosphatidylinositol 3-kinase/Akt pathway and reactive oxygen species. J Biol Chem. 2002;277:31963-31971.
22. Romashkova JA, Makarov SS. NF-kappaB is a target of AKT in antiapoptotic PDGF signalling. [comment] Nature. 1999;401:86-90.
23. Jin KL, Mao XO, Greenberg DA. Vascular endothelial growth factor: direct neuroprotective effect in in vitro ischemia. Proc Natl Acad Sci USA. 2000;97:10242-10247.
24. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
25. Wang JM, Shen W, Su S. Chemokines and their role in cardiovascular diseases. Trends Cardiovasc Med. 1998;8:169-174.
26. Dhawan S, Singh S, Aggarwal BB. Induction of endothelial cell surface adhesion molecules by tumor necrosis factor is blocked by protein tyrosine phosphatase inhibitors: role of the nuclear transcription factor NF-kappa B. Eur J Immunol. 1997;27:2172-2179.
27. Zhao Q, Egashira K, Inoue S, et al. Vascular endothelial growth factor is necessary in the development of arteriosclerosis by recruiting/activating monocytes in a rat model of long-term inhibition of nitric oxide synthesis. Circulation. 2002;105:1110-1115.
28. Celletti FL, Waugh JM, Amabile PG, et al. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med. 2001;7:425-429.
29. Rojas E, Herrera LA, Poirier LA, et al. Are metals dietary carcinogens? Mutat Res. 1999;443:157-181.
30. Rojas E, Valverde M, Herrera LA, et al. Genotoxicity of vanadium pentoxide evaluated by the single cell gel electrophoresis assay in human lymphocytes. Mutat Res. 1996;359:77-84.
31. Roldan RE, Altamirano LM. Chromosomal aberrations, sister-chromatid exchanges, cell-cycle kinetics and satellite associations in human lymphocyte cultures exposed to vanadium pentoxide. Mutat Res. 1990;245:61-65.
32. Sabbioni E, Pozzi G, Pintar A, et al. Cellular retention, cytotoxicity and morphological transformation by vanadium(IV) and vanadium(V) in BALB/3T3 cell lines. Carcinogenesis. 1991;12:47-52.
33. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science. 2001;294:1337-1340.
34. Grunstein J, Roberts WG, Mathieu-Costello O, et al. Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res. 1999;59:1592-1598.